Paul Taylor1, Jonathan Krieger1, Qixin Liu2, Mingjie Xie2, Lian Yang2,3, Bin Ma2,3
1The Hospital for Sick Children, Toronto, ON, Canada
2Rapid Novor Inc., Waterloo, ON, Canada
3University of Waterloo, Waterloo, ON, Canada

Abstract

Monoclonal antibodies (mAbs) are on the rise as biologics in the biopharma industry. To develop robut mAb biologics, it is vital to fully characterize the protein, including its primary sequence, mutations, and important post-translational modifications. Conventionally, this data is gathered by performing several distinct biochemical and molecular biology experiments, which can be time-consuming and costly. Furthermore, when proteomics-based mAb characterization is undertaken, many laboratories lack the bioinformatics capacity and still rely on human analysis, which can result in errors, or in homology-based databases which can introduce bias. As such, traditional antibody characterization may be lengthy and error-prone. Here, we automated a protein sequencing workflow, and show that a fully automated LC-MS/MS-based protein sequencing data analysis can efficiently and fully decode the primary amino acid sequence of an antibody, in addition to denoting post-translational modification (PTM) sites critical for antibody characterization required in biologics development.

Key Takeaways

  • De novo protein sequencing is capable of fully sequencing an antibody
  • De novo protein sequencing can pinpoint PTM sites and the type of PTM
  • De novo protein sequencing is useful tool for antibody characterization

Download the Full Case Study

Whitepaper: Prevalence of Secondary Light Chains

Talk to Our Scientists.

We Have Sequenced 3000+ Antibodies and We Are Eager to Help You.

Through next generation protein sequencing, Rapid Novor enables reliable discovery and development of novel reagents, diagnostics, and therapeutics. Thanks to our Next Generation Protein Sequencing and antibody discovery services, researchers have furthered thousands of projects, patented antibody therapeutics, and developed the first recombinant polyclonal antibody diagnostics.

Talk to Our Scientists.

We Have Sequenced 3000+ Antibodies and We Are Eager to Help You.

Through next generation protein sequencing, Rapid Novor enables timely and reliable discovery and development of novel reagents, diagnostics, and therapeutics. Thanks to our Next Generation Protein Sequencing and antibody discovery services, researchers have furthered thousands of projects, patented antibody therapeutics, and ran the first recombinant polyclonal antibody diagnostics

Talk to our scientists. We have sequenced over 3000 antibodies and we are eager to help you.